ANKET | Innate Pharma

Innate Pharma to present IPH6501 preclinical data at the EHA 2023 congress

May 15, 2023

IPH6501, a first-in-class tetra-specific antibody-based natural killer cell engager therapeutic developed for the treatment of B-cell non-Hodgkin's lymphomas, selected for oral presentation Innate...

Innate Pharma Reports First Quarter 2023 Financial Results And Business Update

May 10, 2023

Exclusive worldwide rights granted to Takeda to research and develop antibody drug conjugates (ADC) using a panel of selected Innate antibodies; Innate to receive $5m upfront payment and eligible to...

Innate Pharma highlights clinical abstracts selected for ASCO 2023 annual meeting

May 3, 2023

Oral presentation on SAR’579 / IPH6101, a potential first-in-class NKp46/CD16-based NK cell engager targeting CD123; SAR’579 / IPH6101 is ANKET ® platform lead asset and under development by partner...

Innate Pharma reports Full Year 2022 Financial Results and Business Update

March 23, 2023

Sanofi collaboration for Natural Killer cell engager therapeutics expanded to B7-H3 ANKET ® program and two additional targets, with €25 million payment Encouraging preliminary TELLOMAK Phase 2...

Innate Pharma announces HSR clearance regarding expansion of its collaboration with Sanofi on NK cell engagers

January 25, 2023

Following expiration of Hart-Scott-Rodino waiting period regarding expansion of their collaboration on NK cell engagers, the licensing agreement between Sanofi and Innate is now effective. Innate...

Innate Pharma announces publication of preclinical data with a trifunctional NK cell engager in acute myeloid leukemia in Nature Biotechnology

January 16, 2023

Data show control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123 These results support clinical development of CD123-NKCE; A Phase 1/2 clinical trial by...

Sanofi and Innate Pharma expand collaboration for Natural Killer cell therapeutics in oncology

December 19, 2022

Sanofi gains exclusive license to Innate’s B7H3 ANKET TM program and options for two additional targets; Upon candidate selection, Sanofi will be responsible for all development, manufacturing and...

Innate Pharma presents data from ongoing Phase 2 TELLOMAK trial demonstrating clinical activity of lacutamab in advanced Sézary syndrome at ASH 2022

December 10, 2022

Lacutamab demonstrated encouraging efficacy and a favorable safety profile in heavily pretreated, post-mogamulizumab patients with advanced Sézary syndrome In addition, Innate’s ANKET TM (Antibody...

IPH6501, Tetra-specific NK cell engager

What is IPH6501?

IPH6501 is the first tetra-specific NK cell engager to engage activating receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor  (via an IL-2 variant, IL-2v) via a single molecule, using Innate’s proprietary multispecific antibody format ANKET^®.

Mechanism of action

Read more about IPH6501, Tetra-specific NK cell engager

Innate Pharma Reports Third Quarter Financial Results

November 14, 2022

Preliminary data from ongoing Phase 2 TELLOMAK trial of lacutamab demonstrated clinical activity in mycosis fungoides, presented at EORTC-CLTG annual meeting Preliminary Sezary syndrome lacutamab...

Subscribe to ANKET

Company
Science
Products
- Pipeline overview
- ------------------
- Lacutamab
- IPH4502
- Monalizumab
- Other Clinical Stage Assets
  - IPH6501
  - IPH6101
  - IPH6401
  - IPH5201
  - IPH5301
Partnering
Investors
Media
Careers